Co-Authors
This is a "connection" page, showing publications co-authored by DEBORAH A KUBAN and SEAN ERIC MCGUIRE.
Connection Strength
2.338
-
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):e39-46.
Score: 0.437
-
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514.
Score: 0.179
-
Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. J Clin Oncol. 2018 10 10; 36(29):2943-2949.
Score: 0.164
-
Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial. Am J Clin Oncol. 2018 Jun; 41(6):558-567.
Score: 0.161
-
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548.
Score: 0.154
-
The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol. 2016 08; 39(4):368-73.
Score: 0.142
-
Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e239-46.
Score: 0.121
-
Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1074-84.
Score: 0.121
-
Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer. 2013 Sep 15; 119(18):3265-71.
Score: 0.115
-
Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):693-9.
Score: 0.107
-
Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer. 2012 Jul; 48(11):1664-71.
Score: 0.104
-
Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J. 2012 Jan-Feb; 18(1):1-8.
Score: 0.103
-
Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center. Clin Transl Radiat Oncol. 2024 Sep; 48:100822.
Score: 0.062
-
Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. Brachytherapy. 2020 Sep - Oct; 19(5):574-583.
Score: 0.047
-
Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):982-985.
Score: 0.046
-
Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open. 2020 03 02; 3(3):e201255.
Score: 0.046
-
Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):790-797.
Score: 0.042
-
Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):374-382.
Score: 0.039
-
Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):249-258.
Score: 0.038
-
Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Dec 01; 87(5):946-53.
Score: 0.029
-
Dosimetric effects of weight loss or gain during volumetric modulated arc therapy and intensity-modulated radiation therapy for prostate cancer. Med Dosim. 2013; 38(3):251-4.
Score: 0.028
-
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy. 2013 May-Jun; 12(3):204-9.
Score: 0.027
-
Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):e7-e13.
Score: 0.026